HHS Awards $5.6M for Tuberculosis Trials and Consortium to Medical University of South Carolina
Contract Overview
Contract Amount: $5,623,130 ($5.6M)
Contractor: THE Medical University of South Carolina
Awarding Agency: Department of Health and Human Services
Start Date: 2021-01-01
End Date: 2026-12-31
Contract Duration: 2,190 days
Daily Burn Rate: $2.6K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 22
Pricing Type: COST NO FEE
Sector: R&D
Official Description: TUBERCULOSIS TRIALS AND CONSORTIUM
Plain-Language Summary
Department of Health and Human Services obligated $5.6 million to THE MEDICAL UNIVERSITY OF SOUTH CAROLINA for work described as: TUBERCULOSIS TRIALS AND CONSORTIUM Key points: 1. Contract awarded to Medical University of South Carolina for TB research. 2. Significant funding allocated to a critical public health area. 3. Potential for advancements in tuberculosis treatment and prevention. 4. Research and Development sector, specifically Biotechnology.
Value Assessment
Rating: good
The contract value of $5.6M over 5 years appears reasonable for a research and development initiative of this scope. Benchmarking against similar large-scale clinical trial consortiums would provide a more precise assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a competitive bidding process. This method generally leads to better price discovery and value for the government.
Taxpayer Impact: The investment supports critical public health research, aiming to improve outcomes and potentially reduce long-term healthcare costs associated with tuberculosis.
Public Impact
Advancements in tuberculosis research could lead to new treatments and diagnostic tools. The consortium will foster collaboration among researchers, potentially accelerating scientific breakthroughs. Improved understanding of tuberculosis could impact global health initiatives and reduce disease burden.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for cost overruns in long-term research projects.
- Reliance on specific research outcomes which may not materialize.
- Ensuring equitable access to developed treatments.
Positive Signals
- Addresses a significant public health challenge.
- Promotes collaboration and knowledge sharing.
- Potential for high-impact scientific discoveries.
Sector Analysis
This contract falls within the Research and Development sector, specifically focusing on Biotechnology. Spending in this area is crucial for innovation but can be subject to long timelines and uncertain outcomes. Benchmarks for similar large-scale R&D contracts are often project-specific.
Small Business Impact
The data does not indicate specific subcontracting opportunities for small businesses. Further analysis would be needed to determine if small businesses are involved or could be engaged in supporting this research.
Oversight & Accountability
The Centers for Disease Control and Prevention (CDC) is the awarding agency, suggesting established oversight mechanisms for research grants and contracts. Regular reporting and milestone reviews are likely in place.
Related Government Programs
- Research and Development in Biotechnology (except Nanobiotechnology)
- Department of Health and Human Services Contracting
- Centers for Disease Control and Prevention Programs
Risk Flags
- Long-term research project with uncertain outcomes.
- Potential for scope creep or evolving research needs.
- Dependence on the expertise and continued participation of key personnel.
- Need for robust data management and security protocols.
Tags
research-and-development-in-biotechnolog, department-of-health-and-human-services, definitive-contract, 1m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $5.6 million to THE MEDICAL UNIVERSITY OF SOUTH CAROLINA. TUBERCULOSIS TRIALS AND CONSORTIUM
Who is the contractor on this award?
The obligated recipient is THE MEDICAL UNIVERSITY OF SOUTH CAROLINA.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).
What is the total obligated amount?
The obligated amount is $5.6 million.
What is the period of performance?
Start: 2021-01-01. End: 2026-12-31.
What is the projected impact of this consortium on tuberculosis treatment efficacy?
The consortium aims to accelerate research into new treatments, diagnostics, and prevention strategies for tuberculosis. By fostering collaboration and pooling resources, it is expected to expedite the discovery and validation of more effective interventions, potentially leading to improved patient outcomes and reduced transmission rates globally. The specific impact will depend on the research findings and their subsequent translation into clinical practice.
What are the primary risks associated with the long-term nature of this research contract?
The primary risks include potential scientific setbacks where research objectives are not met, leading to wasted resources. There's also the risk of budget overruns due to unforeseen complexities in clinical trials or research. Furthermore, the long duration means that scientific priorities or external factors could shift, potentially diminishing the relevance or impact of the research by its conclusion.
How will the effectiveness of the research be measured and ensured?
Effectiveness will likely be measured through predefined research milestones, publication of findings in peer-reviewed journals, and the successful development of new tools or therapies. The CDC's oversight, peer review processes, and adherence to rigorous scientific methodologies are key to ensuring the quality and effectiveness of the research conducted by the consortium.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Solicitation ID: 75D301-20-R-67869
Offers Received: 22
Pricing Type: COST NO FEE (S)
Evaluated Preference: NONE
Contractor Details
Address: 179 ASHLEY AVE, CHARLESTON, SC, 29425
Business Categories: Category Business, Educational Institution, Government, Higher Education, U.S. National Government, Not Designated a Small Business, Higher Education (Public), U.S. Regional/State Government
Financial Breakdown
Contract Ceiling: $9,856,206
Exercised Options: $5,623,130
Current Obligation: $5,623,130
Actual Outlays: $3,433,123
Subaward Activity
Number of Subawards: 2
Total Subaward Amount: $3,084,211
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Timeline
Start Date: 2021-01-01
Current End Date: 2026-12-31
Potential End Date: 2030-12-31 00:00:00
Last Modified: 2025-12-17
More Contracts from THE Medical University of South Carolina
- Federal Contract — $16.9M (Department of Health and Human Services)
View all THE Medical University of South Carolina federal contracts →
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →